1. Mortality among HIV-positive postpartum women with high CD4 cell counts in Zimbabwe
- Author
-
John W, Hargrove, Jean H, Humphrey, and Clare, Zunguza
- Subjects
Adult ,Zimbabwe ,medicine.medical_specialty ,Immunology ,Population ,Acquired immunodeficiency syndrome (AIDS) ,Pregnancy ,Antiretroviral Therapy, Highly Active ,Case fatality rate ,HIV Seropositivity ,medicine ,Immunology and Allergy ,Humans ,education ,education.field_of_study ,business.industry ,Obstetrics ,Mortality rate ,Postpartum Period ,Viral Load ,medicine.disease ,Prognosis ,Confidence interval ,CD4 Lymphocyte Count ,Infectious Diseases ,HIV-1 ,RNA, Viral ,Female ,business ,Postpartum period ,Cohort study - Abstract
BACKGROUND: Whereas HAART initiated at CD4 cell counts 351-450 cells/ml reduces mortality compared with starting at lower CD4 levels there is currently no evidence for the advantages of initiating treatment at CD4 cell counts greater than 450 cells/ml. METHODS: Mortality hazard as a function of CD4 cell count was estimated among postpartum HIV-positive women in Zimbabwe using HIV-negative women as the reference group. RESULTS: Mortality within 24 months postpartum was 54 times higher among women with CD4 cell counts less than 200 cells/ml fell to 5.4 times higher for those with CD4 cell counts 400-600 cells/ml but fell little thereafter. For CD4 cell counts greater than 600 cells/ml the hazard was 6.2 (95% confidence interval 3.2-11.9). CONCLUSION: Early HAART initiation for all HIV-positive pregnant women may benefit individual mothers and infants and simultaneously reduce population HIV incidence.
- Published
- 2010